Pharmacogenomics and Personalized Medicine最新文献

{"title":"The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy.","authors":"Jia He,&nbsp;Zhan Wang,&nbsp;Ying Wang,&nbsp;Ting Zou,&nbsp;Xiang-Ping Li,&nbsp;Lei Cao,&nbsp;Juan Chen","doi":"10.2147/PGPM.S325788","DOIUrl":"https://doi.org/10.2147/PGPM.S325788","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the relationships between Wnt1 inducible signaling pathway protein 1 (WISP1) polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients.</p><p><strong>Patients and methods: </strong>A total of 363 lung cancer patients were recruited in this study. All of them received at least two cycles of platinum-based chemotherapy. We used unconditional logistic regression analysis to assess the associations of 39 single nucleotide polymorphisms in WISP1 gene with platinum-based chemotherapy prognosis.</p><p><strong>Results: </strong>The results indicated that patients carried rs2929973 GT or GG genotypes had increased risk of disease progression (HR = 0.712, 95% CI = 0.553-0.916, <i>P</i> = 0.015). Patients with rs2977551 TT genotype had a significantly decreased risk of progression-free survival than patients carrying CT or CC genotype (HR = 0.723, 95% CI = 0.561-0.932, <i>P</i> = 0.032) and overall survival (HR = 0.725, 95% CI = 0.552-0.913, <i>P</i> = 0.045). For rs2977549, patients carrying TT genotype had a significantly longer progression-free survival than patients with CC or CT genotypes (HR = 0.708, 95% CI = 0.550-0.912, <i>P</i> = 0.017). Among of them, rs16904853, rs10956697, rs2929965, rs2929973, rs7828685, rs2977551 and rs2977549 were related to progression-free survival, and rs10956697 and rs2977551 were related to overall survival in subgroup analyses, respectively.</p><p><strong>Conclusion: </strong>WISP1 rs2929973, rs2977551 and rs2977549 may be contributed to a potential candidate biomarker for prediction of platinum-based chemotherapy prognosis in lung cancer patients.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1193-1203"},"PeriodicalIF":1.9,"publicationDate":"2021-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/ec/pgpm-14-1193.PMC8458023.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39451175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Gene Variations of <i>GABRA2, GABRB1, GABRG2, GAD1</i> and <i>SLC1A3</i> on Patients with Propofol During Anesthesia Induction.","authors":"Lingyi Zhang,&nbsp;Zhuoling Zheng,&nbsp;Wudi Ma,&nbsp;Shuyu Zhang,&nbsp;Faling Xue,&nbsp;Haini Wang,&nbsp;Yongqi He,&nbsp;Fang Ye,&nbsp;Shouning Zhou,&nbsp;Yongzi Wen,&nbsp;Xiaoyan Li,&nbsp;Wenqi Huang,&nbsp;Min Huang,&nbsp;Jiali Li,&nbsp;Zhongxing Wang","doi":"10.2147/PGPM.S326885","DOIUrl":"https://doi.org/10.2147/PGPM.S326885","url":null,"abstract":"<p><strong>Purpose: </strong>Propofol is one of the most commonly used intravenous sedatives in general anesthesia, while the individual variations of propofol are apparent. The objective of this study was to investigate the influence of genetic variations in GABAergic neurons and glutamatergic neurons on time to loss of consciousness (LOC) and the incidence of hypotension during anesthesia induction.</p><p><strong>Patients and methods: </strong>A total of 140 Chinese patients undergoing thyroid surgery or breast surgery were recruited. Genotyping of candidate genes was carried out using the Agena Bioscience MassARRAY system. Anesthesia induction was initiated with a propofol target plasma concentration (Cp) of 4.0 μg mL^-1. The LOC latency, systolic blood pressure, diastolic blood pressure, mean arterial pressure were documented.</p><p><strong>Results: </strong>We found that <i>GABRA2</i> rs35496835, <i>GABRB1</i> rs1372496, <i>GABRG2</i> rs11135176, <i>GABRG2</i> rs209358, <i>GAD1</i> rs3791878, <i>SLC1A3</i> rs1049522 and gender were significant determinants of the patient's LOC latency following propofol administration. <i>GABRA2</i> rs11503014 was highly correlated with blood pressure reduction during anesthesia induction. Multiple linear regression analysis revealed that <i>GABRB1</i> rs1372496, <i>GABRG2</i> rs11135176, and <i>SLC1A3</i> rs1049522 accounted for 35.3% variations in LOC latency following propofol administration.</p><p><strong>Conclusion: </strong>Our findings indicate that genetic variants of <i>GABRA2, GABRB1, GABRG2, GAD1</i> and <i>SLC1A3</i> may have influence on propofol susceptibility, which would be an important guidance towards building clinical models that can precisely predict the efficacy of propofol with various populations before surgery.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1185-1192"},"PeriodicalIF":1.9,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/d9/pgpm-14-1185.PMC8455292.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39442757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>DZIP1</i> Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis.","authors":"Yuan-Jie Liu,&nbsp;Jie-Pin Li,&nbsp;Shu-Hong Zeng,&nbsp;Mei Han,&nbsp;Shen-Lin Liu,&nbsp;Xi Zou","doi":"10.2147/PGPM.S325701","DOIUrl":"https://doi.org/10.2147/PGPM.S325701","url":null,"abstract":"<p><strong>Purpose: </strong>Gastric cancer (GC) is a common type of cancer worldwide. It can relapse and metastasize even after standard treatment; therefore, it has a poor prognosis. Moreover, sensitive biomarkers for prognosis prediction in GC are lacking. In this study, using a bioinformatics approach, we aimed to examine the value of DAZ Interacting Protein 1 (<i>DZIP1</i>) as a prognostic predictor and therapeutic target in GC.</p><p><strong>Methods: </strong>We explored the clinical relevance, function, and molecular role of <i>DZIP1</i> in GC using MethSurv, cBioPortal, TIMER, Gene Expression Profiling Interactive Analysis, IMEx, ONCOMINE, MEXPRESS, and EWAS Atlas databases. The GSE118919 dataset was used to plot receiver operating characteristic curves. Using The Cancer Genome Atlas, we developed a Cox regression model and assessed the clinical significance of <i>DZIPs</i>. In addition, we used the \"xCELL\" algorithm to make reliable immune infiltration estimations. Western blot and immunohistochemistry were used to examine protein expression. The results were visualized with the 'ggplot2' and \"circlize\" packages.</p><p><strong>Results: </strong>In GC patients, <i>DZIP1</i> was over-expressed at both the mRNA and protein levels. High levels of <i>DZIP1</i> were found to be associated with poor survival in patients with GC. Our results indicated that <i>DZIP1</i> could be involved in multiple cancer-related pathways such as the PI3K-Akt signaling pathway, WNT signaling pathway, and RAS signaling pathway, and its expression was correlated with the infiltration of activated myeloid dendritic cells, naive CD4+ T cells, and naive CD8+ T cells. Furthermore, we found that mutations in <i>DZIP1</i> were correlated with a good prognosis in GC patients. Finally, we demonstrated a correlation between hypomethylation of the <i>DZIP1</i> gene promoter and a poor prognosis in GC.</p><p><strong>Conclusion: </strong>This study is the first to demonstrate a significant correlation between high levels of <i>DZIP1</i> and a poor prognosis in GC patients. Our results clarify multiple potential mechanisms that could contribute to this correlation and may thus provide novel insights into the clinical diagnosis and treatment of GC.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1151-1168"},"PeriodicalIF":1.9,"publicationDate":"2021-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/f7/pgpm-14-1151.PMC8453447.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39442755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Processes are Potential Biological Processes Distinguishing Nonischemic Dilated Cardiomyopathy from Ischemic Cardiomyopathy: A Clue from Serum Proteomics.","authors":"Guangyong Huang,&nbsp;Zhiqi Huang,&nbsp;Yunling Peng,&nbsp;Yuehai Wang,&nbsp;Weitao Liu,&nbsp;Yuzeng Xue,&nbsp;Wenbo Yang","doi":"10.2147/PGPM.S323379","DOIUrl":"https://doi.org/10.2147/PGPM.S323379","url":null,"abstract":"<p><strong>Background: </strong>Ischemic cardiomyopathy (ICM) and nonischemic dilated cardiomyopathy (DCM) are the two most common causes of heart failure. However, our understanding of the specific proteins and biological processes distinguishing DCM from ICM remains insufficient.</p><p><strong>Materials and methods: </strong>The proteomics analyses were performed on serum samples from ICM (n=5), DCM (n=5), and control (n=5) groups. Proteomics and bioinformatics analyses, including weighted gene co-expression network analysis (WGCNA) and gene set enrichment analysis (GSEA), were performed to identify the hub circulating proteins and the hub biological processes in ICM and DCM.</p><p><strong>Results: </strong>The analysis of differentially expressed proteins and WGCNA identified the hub circulating proteins in ICM (GAPDH, CLSTN1, VH3, CP, and ST13) and DCM (one downregulated protein, FGG; 18 upregulated proteins, including HEL-S-276, IGK, ALDOB, HIST1H2BJ, HEL-S-125m, RPLP2, EL52, NCAM1, P4HB, HEL-S-99n, HIST1H4L, HIST2H3PS2, F8, ERP70, SORD, PSMA3, PSMB6, and PSMA6). The mRNA expression of the heart specimens from GDS651 validated that ALDOB, GAPDH, RPLP2, and IGK had good abilities to distinguish DCM from ICM. In addition, GSEA results showed that cell proliferation and differentiation were the hub biological processes related to ICM, while metabolic processes and cell signaling transduction were the hub biological processes associated with DCM.</p><p><strong>Conclusion: </strong>The present study identified five dysregulated hub circulating proteins among ICM patients and 19 dysregulated hub circulating proteins among DCM patients. Cell proliferation and differentiation were significantly enriched in ICM. Metabolic processes were strongly enhanced in DCM and may be used to distinguish DCM from ICM.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1169-1184"},"PeriodicalIF":1.9,"publicationDate":"2021-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/19/pgpm-14-1169.PMC8453897.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39442756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Polymorphism of <i>GABRG2</i> rs211037 is Associated with Drug Response and Adverse Drug Reactions to Valproic Acid in Chinese Southern Children with Epilepsy.","authors":"Jieluan Lu,&nbsp;Hanbing Xia,&nbsp;Wenzhou Li,&nbsp;Xianhuan Shen,&nbsp;Huijuan Guo,&nbsp;Jianping Zhang,&nbsp;Xiaomei Fan","doi":"10.2147/PGPM.S329594","DOIUrl":"https://doi.org/10.2147/PGPM.S329594","url":null,"abstract":"<p><strong>Background: </strong>Valproic acid (VPA) is recommended as a first-line treatment for children with epilepsy. <i>GABRG2</i> polymorphism is found to be associated with epilepsy susceptibility and therapeutic response of anti-seizure medications (ASM); however, the role of <i>GABRG2</i> in VPA treatment still remains unknown.</p><p><strong>Objective: </strong>The purpose of this study was to explore the association of <i>GABRG2</i> gene polymorphism with the drug response and adverse drug reactions (ADRs) related to VPA.</p><p><strong>Methods: </strong>A retrospective study including 96 Chinese children with epilepsy treated by VPA was carried out. The ADRs were collected during VPA therapy and <i>GABRG2</i> rs211037 in enrolled patients was genotyped using Sequenom MassArray system. A network pharmacological analysis involved protein-protein interaction and enrichment analysis was constructed to investigate the potential targets and pathways of <i>GABRG2</i> on VPA-related ADRs.</p><p><strong>Results: </strong>Among 96 patients, 41 individuals were defined as seizure together with 49 patients with seizure-free and 6 patients unclassified. Carriers of homozygote <i>GABRG2</i> rs211037 CC genotype exhibited seizure-free to VPA (<i>P</i> = 0.042), whereas those with CT genotype showed seizure. Furthermore, CC genotype had predisposition to digestive ADRs (<i>P</i> = 0.037) but was a protective factor for VPA-associated weight gain (<i>P</i> = 0.013). Ten key genes related to digestive ADRs and weight gain induced by VPA were identified by network pharmacological analysis and mainly involved in \"GABAergic synaptic signaling\", \"GABA receptor signaling\", and \"taste transduction\" pathways/processes through enrichment analysis.</p><p><strong>Conclusion: </strong>This study revealed that <i>GABRG2</i> variation exerted a predictable role in the efficacy and safety of VPA treatment for Chinese children with epilepsy.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1141-1150"},"PeriodicalIF":1.9,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/2a/pgpm-14-1141.PMC8450188.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39439214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gephyrin and <i>CYP2C9</i> Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy.","authors":"Hamdy N El-Tallawy,&nbsp;Sawsan Abuhamdah,&nbsp;Ahmed Y Nassar,&nbsp;Wafaa M A Farghaly,&nbsp;Tahia H Saleem,&nbsp;Sara A Atta,&nbsp;Ayat A Sayed,&nbsp;Amal M Tohamy,&nbsp;Mohammed H Hassan","doi":"10.2147/PGPM.S327808","DOIUrl":"https://doi.org/10.2147/PGPM.S327808","url":null,"abstract":"<p><strong>Purpose: </strong>Gephyrin (<i>GPHN</i>) is an essential protein in the regulation of inhibitory postsynaptic density and polymorphism in the corresponding gene may have a role in the development of pharmacoresistant epilepsy (PRE). For the first time, we aimed to evaluate the association of rs928553T/C variants with PRE susceptibility. Moreover, we have analyzed the genetic polymorphism affecting <i>CYP2C9</i> \"rs12782374G/A\" in the same population to detect the effect of SNP on the drug-metabolizing ability of patients with PRE.</p><p><strong>Patients and methods: </strong>This case-control study enrolled 100 patients (group A) and 100 healthy, age and sex-matched controls, unrelated to patients (group B). TaqMan™ assays using real-time PCR were run for genotyping of rs928553T/C and rs12782374G/A in all participants.</p><p><strong>Results: </strong><i>GPHN</i> T>C polymorphism revealed significant risk association with occurrence of PRE using dominant, recessive and codominant models as follows: TT vs (TC+CC): OR 0.23, 95%CI: 0.13-0.43, <i>P</i><0.001. In addition, (TT+TC vs CC): OR 0.38, 95%CI: 0.18-0.77, <i>P</i><0.001. Also, T vs C (OR 0.34, 95%CI: 0.22-0.51, <i>P</i>=<0.001). Similarly, <i>CYP2C9</i> G>A polymorphism showed a significant increased risk of PRE (GG vs (GA+AA): OR 0.11, 95%CI: 0.05-0.23, <i>P</i><0.001). Furthermore, (GG+GA vs AA): OR 0.18, 95%CI: 0.084-0.39, <i>P</i><0.001. Also, G vs A (OR 0.24, 95%CI: 0.15-0.366, <i>P</i>=<0.001).</p><p><strong>Conclusion: </strong>Mutation of both <i>GPHN</i> (rs928553) and <i>CYP2C9</i> (rs1278237) genes may be implicated as a genetic mediators of resistance in patients with PRE.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1133-1140"},"PeriodicalIF":1.9,"publicationDate":"2021-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/ae/pgpm-14-1133.PMC8437390.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39420182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Search for Possible Associations of <i>FTO</i> Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients.","authors":"Anastasiia S Boiko,&nbsp;Ivan V Pozhidaev,&nbsp;Diana Z Paderina,&nbsp;Anna V Bocharova,&nbsp;Irina A Mednova,&nbsp;Olga Yu Fedorenko,&nbsp;Elena G Kornetova,&nbsp;Anton J M Loonen,&nbsp;Arkadiy V Semke,&nbsp;Nikolay A Bokhan,&nbsp;Svetlana A Ivanova","doi":"10.2147/PGPM.S327353","DOIUrl":"https://doi.org/10.2147/PGPM.S327353","url":null,"abstract":"<p><strong>Purpose: </strong>Metabolic syndrome (MetS) is characterized by abdominal obesity, hyperglycaemia, dyslipidaemia and hypertension. FTO gene has been implicated in the pathogenesis of obesity, but the available scientific data concerning their relationship to antipsychotic drug-induced obesity and metabolic syndrome is still incomplete and inconsistent, which indicates that continuing the investigation of this gene's role is necessary.</p><p><strong>Patients and methods: </strong>In the present study, 517 patients with schizophrenia underwent antipsychotic drug treatment, and two groups were identified: patients with MetS and without MetS. Genotyping of 6 SNPs in the FTO gene was performed, and the results analyzed using R-programme.</p><p><strong>Results: </strong>We performed a statistical analysis to identify possible associations of the frequencies of genotypes and alleles of the studied polymorphisms with the presence of metabolic syndrome in schizophrenia patients, with the presence of abdominal obesity, and with an increased body mass index. The rs7185735 polymorphism did not meet the Hardy-Weinberg criterion and was excluded. After correcting for differences in age, gender and duration of illnesses, none of the variants was shown to be related to metabolic syndrome or abdominal obesity, but rs9939609, rs1421085, rs3751812 and rs8050136 were associated with body mass index.</p><p><strong>Conclusion: </strong>The present study provides additional support for these SNP's roles as a pharmacogenetic biomarker that may become useful in the framework of the personalized medicine approach.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1123-1131"},"PeriodicalIF":1.9,"publicationDate":"2021-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/ff/pgpm-14-1123.PMC8434933.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39435642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking, Hypertension, and GG Genotype of the IL-6 rs1800796 Polymorphism are Independent Risk Factors for Abdominal Aortic Aneurysm in Han Population.","authors":"Yuchao Zhang,&nbsp;Gang Xu,&nbsp;Ping Wang","doi":"10.2147/PGPM.S328894","DOIUrl":"https://doi.org/10.2147/PGPM.S328894","url":null,"abstract":"<p><strong>Background: </strong>Recent researches have investigated the link between the rs1800796 polymorphism (-572G/C) in the interleukin-6 (IL-6) gene and the risk of abdominal aortic aneurysm (AAA). However, no Chinese studies have addressed the association between the risk of AAA and this polymorphism.</p><p><strong>Methods: </strong>This case-control study included 153 AAA patients and 205 controls. Diabetes mellitus, hypertension, dyslipidemia, and coronary artery disease (CAD) status were collected. The AAA and control groups were 69.20 ± 7.56 and 68.50 ± 7.12 years old, respectively.</p><p><strong>Results: </strong>The analysis revealed that the G allele and GG genotype of the IL-6 rs1800796 polymorphism were remarkedly correlated with an elevated risk of AAA. The GG genotype displayed an association with the risk of AAA after adjustment for gender, body mass index, age, drinking, and smoking. Subgroup analyses indicated that this polymorphism elevated the risk of AAA among males, individuals aged ≥70 years, smokers, drinkers, individuals with a body mass index (BMI) ≥25 kg/m², patients without diabetes, and patients with hypertension. Univariate and multivariate analyses indicated that smoking, hypertension, and the GG genotype (rs1800796 polymorphism) were independently related with the risk of AAA.</p><p><strong>Conclusion: </strong>The IL-6 rs1800796 polymorphism increases the risk of AAA. In addition, smoking, hypertension, and the GG genotype of the rs1800796 polymorphism are independent risk factors for AAA. Further studies of Chinese populations are needed to validate these findings.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1115-1121"},"PeriodicalIF":1.9,"publicationDate":"2021-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/62/pgpm-14-1115.PMC8434934.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39435640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Risk Factors of Lower-Extremity Deep Vein Thrombosis After Thrombolysis Among Patients with Acute Ischemic Stroke.","authors":"Zhuo Liu,&nbsp;Dandan Liu,&nbsp;Zhen-Ni Guo,&nbsp;Hang Jin,&nbsp;Tong Sun,&nbsp;Chunping Ni,&nbsp;Xiuli Yan","doi":"10.2147/PGPM.S321084","DOIUrl":"https://doi.org/10.2147/PGPM.S321084","url":null,"abstract":"<p><strong>Background: </strong>Deep vein thrombosis (DVT) is common among patients with stroke. However, the incidence of DVT in acute ischemic stroke patients treated with thrombolytic therapy and the risk factors associated with this condition are unknown.</p><p><strong>Objective: </strong>This study aimed to investigate the incidence and risk factors of DVT after thrombolysis in patients with acute ischemic stroke.</p><p><strong>Settings and methods: </strong>We retrospectively reviewed the medical records of all patients with acute ischemic stroke who underwent ultrasonic examination after intravenous thrombolysis between April 2017 and December 2019 at the stroke center of the First Hospital of Jilin University, China. Color duplex ultrasound was used to diagnosis DVT in all patients within 72 h after intravenous thrombolysis. Univariate and multivariate logistic regression analyses were performed to identify the risk factors for DVT.</p><p><strong>Results: </strong>Overall, 474 patients were included in the study. Of these, 75 (15.8%) developed DVT (95% confidence interval 12.5-19.1). Older age was the risk factor that most significantly affected the development of DVT (<i>p</i> = 0.001). Compared to patients younger than 60 years old, those aged 60-69 years and ≥70 years had a higher risk of DVT, at rates of 2.201 (95% CI: 1.033-4.689; <i>p</i> < 0.05) and 4.241 (95% CI: 2.016-8.922; <i>p</i> < 0.001) times higher, respectively. Patients with higher triglyceride levels (odds ratio 0.545, 95% CI: 0.372-0.799, <i>p</i> = 0.002) and longer activated partial thromboplastin time (OR 0.927, 95% CI: 0.862-0.996, <i>p</i> = 0.040) were less likely to have DVT.</p><p><strong>Conclusion: </strong>DVT is a common complication among patients undergoing intravenous thrombolysis after acute ischemic stroke. Advanced age may increase the occurrence of DVT to some extent. For these patients, safe antiplatelet therapy should be explored and implemented as soon as possible.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1107-1114"},"PeriodicalIF":1.9,"publicationDate":"2021-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/28/pgpm-14-1107.PMC8427686.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39408177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis.","authors":"Lizhi Chen,&nbsp;Yunyun Yang,&nbsp;Xuebin Wang,&nbsp;Chenyu Wang,&nbsp;Weiwei Lin,&nbsp;Zheng Jiao,&nbsp;Zhuo Wang","doi":"10.2147/PGPM.S321997","DOIUrl":"https://doi.org/10.2147/PGPM.S321997","url":null,"abstract":"<p><strong>Purpose: </strong>In this study, we aimed to establish a tacrolimus population pharmacokinetic model and better understand the drug-drug interaction between Wuzhi capsule and tacrolimus in Chinese renal transplant recipients.</p><p><strong>Patients and methods: </strong>We performed a population pharmacokinetic analysis using a non-linear mixed-effects model to determine the suitable Wuzhi capsule dose in combination with tacrolimus. Data on 1378 tacrolimus steady-state concentrations were obtained from 142 patients who received kidney transplant in Changhai Hospital and Huashan Hospital. Demographic characteristics, laboratory tests, genetic polymorphisms, and co-medications were evaluated.</p><p><strong>Results: </strong>The one-compartment model best described data. Our final model identified creatinine clearance rate, hematocrit, Wuzhi capsule dose, <i>CYP3A5*3</i> genetic polymorphisms, and tacrolimus daily dose as significant covariates for tacrolimus clearance, with the value of 14.4 L h^-1, and the between-subject variability (BSV) was 25.4%. The Wuzhi capsule showed a dose-dependent effect on tacrolimus pharmacokinetics, demonstrating a stronger inhibitory effect than inductive effect.</p><p><strong>Conclusion: </strong>Our model can accurately describe population pharmacokinetics of tacrolimus when combined with different doses of Wuzhi capsule. Additionally, this model can be used for individualizing tacrolimus dose following kidney transplantation.</p>","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"1093-1106"},"PeriodicalIF":1.9,"publicationDate":"2021-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/a1/pgpm-14-1093.PMC8423491.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39408176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}